Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17407518 | 0.85 | KIF11 (0.44) | KIF11CYP11B2CYP11B1SLC7A5KDM1A | |
| SCHEMBL13863765 | 0.79 | KIF11 (0.46) | KIF11CYP11B2CYP11B1SLC7A5KDM1A | |
| SCHEMBL177527 | 0.78 | MRGPRX4 (0.42) | — | |
| SCHEMBL15305003 | 0.78 | CYP11B2 (0.59) | KIF11CYP11B2CYP11B1SLC7A5 | |
| SCHEMBL27444630 | 0.78 | KIF11 (0.44) | KIF11CYP11B2CYP11B1SLC7A5KDM1A | |
| SCHEMBL177743 | 0.76 | SOS1 (0.41) | — | |
| SCHEMBL28741512 | 0.76 | KIF11 (0.45) | KIF11CYP11B2CYP11B1SLC7A5 | |
| SCHEMBL177583 | 0.74 | IDO1 (0.46) | — | |
| SCHEMBL28831287 | 0.73 | KIF11 (0.44) | KIF11CYP11B2CYP11B1SLC7A5KDM1A | |
| SCHEMBL16418700 | 0.73 | KIF11 (0.49) | KIF11CYP11B2CYP11B1SLC7A5KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106281356-A | Fluorinated liquid crystal containing difluoro-methoxy bridged bond and diyl and combinations thereof thing | 福建省邵武市永晶化工有限公司 | 2017-01-04 | — | — | CN | disclosed |
| CN-106244168-A | Fluorinated liquid crystal containing difluoro-methoxy bridged bond and polyfluoro xenyl and combinations thereof thing | 福建永晶科技有限公司 | 2016-12-21 | — | — | CN | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| CN-104449762-B | Fluorine-containing liquid crystal containing difluoromethoxy bridge bond and composition thereof | 福建省邵武市永晶化工有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876109-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2015-05-27 | — | — | EP | disclosed |
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011022348-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | WO | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PIK3CD, PIK3CA, MTOR | KIF11 3806/4885CYP11B2 159/4885CYP11B1 136/4885 |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | KIF11 4742/4885CYP11B2 2454/4885CYP11B1 2054/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | KIF11 4100/4885CYP11B2 1975/4885CYP11B1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.